ClinicalTrials.gg
CompletedNCT02879578Updated Apr 29, 2021Results posted

Safety and Tolerability Study of NBI-98854 for the Treatment of Subjects With Tourette Syndrome

A Phase 2 interventional study of Valbenazine in Tourette Syndrome, sponsored by Neurocrine Biosciences. Completed at 13 sites in United States. Open to participants aged 6 Years to 64 Years. Per ClinicalTrials.gov, last updated 2021-04-29.

Sponsored by Neurocrine Biosciences · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
155
Allocation
Non-randomized
Ages
6 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 139 studies in Tourette Syndrome with a site in United States — 20 open to participants now, 24 under way, 1 of them phase 3. Tourette Syndrome · United States.

Enrollment
12th of 105
155 · median 33
Started
2016
with 4 others
Phase 2
26 of 139
4 open now
Registered
76th of 139
by date
Lead sponsor
8 of 139
Neurocrine Biosciences

Among the 139 studies in Tourette Syndrome with a site in United States, this one is the 12th largest by enrollment of the 105 interventional ones that give a count, is one of 5 that started in 2016, is one of 26 in phase 2, and was the 76th registered.

Tourette Syndrome

240 studies on the registry are indexed under Tourette Syndrome; 40 are open to participants now.

Browse Tourette Syndrome studies →

Open to participants now

20 of the 139 studies in Tourette Syndrome with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 33 Tourette Syndrome studies recruiting now, 9 (27%) set no upper age limit and 22 (67%) stop at 75 or younger; 20 take children under 18; 9 take healthy volunteers.

This study: 6 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 139 studies in Tourette Syndrome with a site in United States, or all of them as a file.
02

Study summary

Phase 2, open-label, fixed-dose titration study to evaluate the safety and tolerability of NBI-98854 administered once daily for a total of 24 weeks in children, adolescents, and adults with Tourette Syndrome (TS).

03

Conditions studied

  • Tourette Syndrome

Browse trials for

04

Who can participate

Ages eligible
6 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have participated in and completed the NBI-98854-1501 (T-Force Green) or NBI-98854-1505 (T-Forward) Phase 2 study
  • Have a clinical diagnosis of Tourette Syndrome (TS)
  • If using maintenance medication(s) for TS or TS spectrum diagnoses (e.g. obsessive-compulsive disorder [OCD], Attention-Deficit Hyperactivity Disorder [ADHD]), be on stable doses
  • Subjects of who do not practice total abstinence must agree to use hormonal or two forms of nonhormonal (dual contraception) consistently during the screening, treatment and follow-up periods of the study
  • Adolescent and adult subjects (12 to 64 years of age) must have a negative urine drug screen for amphetamines, barbiturates, benzodiazepine, phencyclidine, cocaine, opiates, or cannabinoids and a negative alcohol screen. Subjects who are on stable doses of prescribed and supervised (not as needed) benzodiazepines, opiates, or psychostimulants (for subjects with comorbid ADHD) are allowed to participate in the study
  • Be in good general health

Exclusion criteria

Exclusion Criteria:

  • Have an active, unstable medical condition within 1 month prior to screening
  • Have a known history of long syndrome or cardiac arrhythmia
  • Have a known history of neuroleptic malignant syndrome
  • Have a cancer diagnosis within 3 years prior to screening (some exceptions allowed)
  • Have a blood loss ≥250 mL or donated blood within 56 days prior to screening (subjects 6 to 17 years of age); have a blood loss ≥550 mL or donated blood within 30 days prior to screening (subjects 18 to 64 years of age)
  • Have a known history of substance dependence, substance (drug) or alcohol abuse
  • Have a significant risk of suicidal or violent behavior
  • Have initiated Comprehensive Behavioral Intervention for Tics (CBIT) during the screening period or at baseline or plan to initiate CBIT during the study
  • Have received an drug within 30 days before screening or plan to use an investigational drug (other than NBI-98854) during the study
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
155 participants (actual)

Study arms

  • Experimental
    Valbenazine (Children)

    Children (6 to 11 years of age) received valbenazine 10 mg once daily for 4 weeks. At the end of Week 4, investigators could escalate the dose to 20 mg or continue with the participant's current dose for the remainder of the treatment period.

    Drug: Valbenazine

  • Experimental
    Valbenazine (Adolescents)

    Adolescents (12 to 17 years of age) received valbenazine 20 mg once daily for 4 weeks. At the end of Week 4, investigators could escalate the dose to 40 mg or continue with the participant's current dose for the remainder of the treatment period.

    Drug: Valbenazine

  • Experimental
    Valbenazine (Adults)

    Adults (18 to 64 years of age) received valbenazine 40 mg once daily for 4 weeks. At the end of Week 4, investigators could escalate the dose to 80 mg or continue with the participant's current dose for the remainder of the treatment period.

    Drug: Valbenazine

Interventions

06

What researchers measure

Primary outcomes

  1. Frequency of Treatment-emergent Adverse Events (TEAEs)

    A TEAE is an adverse event not present prior to the initiation of study drug dosing, or is an already present event that worsens either in intensity or frequency following the initiation of study drug dosing.

    Time frame: Baseline through Week 28

07

Results

Posted Apr 29, 2021

Participant flow

The study enrolled male and female children (6 to 11 years of age), adolescents (12 to 17 years of age), and adults (18 to 64 years of age) from 34 centers in the United States. Participants must have a clinical diagnosis of Tourette Syndrome (TS) and must have previously completed participation in Study NB-98854-1501 or Study NBI-98854-1505. The first and last participant were enrolled on 25 July 2016 and 14 April 2017, respectively.

Participant flow — Overall Study
MilestoneValbenazine (Children)Valbenazine (Adolescents)Valbenazine (Adults)
Started334181
Safety analysis set334079
Completed233249
Not completed10932
Withdrew: Adverse event1214
Withdrew: Protocol violation011
Withdrew: Withdrawal by subject869
Withdrew: Lost to follow-up104
Withdrew: Physician decision004

Outcome measures

PrimaryFrequency of Treatment-emergent Adverse Events (TEAEs)

A TEAE is an adverse event not present prior to the initiation of study drug dosing, or is an already present event that worsens either in intensity or frequency following the initiation of study drug dosing.

Time frame:
Baseline through Week 28
Reported as:
Count of participants · Participants
Frequency of Treatment-emergent Adverse Events (TEAEs)
ParticipantsValbenazine (Children)Valbenazine (Adolescents)Valbenazine (Adults)
Frequency of Treatment-emergent Adverse Events (TEAEs)202968

Adverse events

Collected over Up to 28 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Valbenazine (Children)0/33 (0%)0/33 (0%)19/33 (57.6%)
Valbenazine (Adolescents)0/40 (0%)0/40 (0%)22/40 (55%)
Valbenazine (Adults)0/79 (0%)2/79 (2.5%)57/79 (72.2%)
Most frequent serious events
Most frequent serious events
EventValbenazine (Children)Valbenazine (Adolescents)Valbenazine (Adults)
Extrapyramidal disorderNervous system disorders0/330/401/79
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/330/401/79
Most frequent other events
Showing 10 of 21
Most frequent other events
EventValbenazine (Children)Valbenazine (Adolescents)Valbenazine (Adults)
SomnolenceNervous system disorders3/338/4016/79
SedationNervous system disorders3/338/4012/79
FatigueGeneral disorders5/334/4013/79
HeadacheNervous system disorders5/335/405/79
Upper respiratory tract infectionInfections and infestations2/332/4011/79
InsomniaPsychiatric disorders2/335/403/79
IrritabilityGeneral disorders4/330/402/79
VomitingGastrointestinal disorders3/332/401/79
DepressionPsychiatric disorders1/330/407/79
Weight increasedInvestigations2/333/403/79

Baseline characteristics

Safety analysis set, which includes all participants who received at least one dose of study drug and have any postbaseline data.

Age, Continuous
Age, Continuous(Years)Valbenazine (Children)Valbenazine (Adolescents)Valbenazine (Adults)Total
Mean9.5 ± 1.513.7 ± 1.434.6 ± 12.923.6 ± 14.8
Sex: Female, Male
Sex: Female, Male(Participants)Valbenazine (Children)Valbenazine (Adolescents)Valbenazine (Adults)Total
Female782540
Male263254112
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Valbenazine (Children)Valbenazine (Adolescents)Valbenazine (Adults)Total
Hispanic or Latino36413
Not Hispanic or Latino303475139
Unknown or Not Reported0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Valbenazine (Children)Valbenazine (Adolescents)Valbenazine (Adults)Total
Race — American Indian or Alaska Native0000
Race — Asian0011
Race — Black or African American3216
Race — White303576141
Race — Native Hawaiian or Other Pacific Islander0000
Race — Other0101
Race — Multiple0213
08

Study locations

13 sites
  • Sun City, Arizona, United States
  • San Diego, California, United States
  • Loxahatchee Groves, Florida, United States
  • Saint Petersburg, Florida, United States
  • Tampa, Florida, United States
  • Naperville, Illinois, United States
  • Lincoln, Nebraska, United States
  • Summit, New Jersey, United States
  • New York, New York, United States
  • Norristown, Pennsylvania, United States
  • Nashville, Tennessee, United States
  • Fort Worth, Texas, United States
  • Spokane, Washington, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2016 to primary completion in Nov 2017, 15 months.

Results were first posted in Apr 2021, 3 years 5 months after primary completion. A results delay was requested in Mar 2019.

Of 19 phase 2 interventional studies under Tourette Syndrome, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 42. This study's 15 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2016
First posted
Aug 25, 2016
StartActual
Jul 25, 2016
Primary completionActual
Nov 1, 2017
CompletionActual
Nov 1, 2017
Results delay requested
Mar 11, 2019
Results first posted
Apr 29, 2021
Last update
Apr 29, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02879578
Responsible party
Sponsor
First posted
Aug 25, 2016
Start date
Jul 25, 2016
Primary completion
Nov 1, 2017
Completion
Nov 1, 2017
Results posted
Apr 29, 2021
Last update
Apr 29, 2021

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Valbenazine

Start the discussion